METHOD FOR REDUCTION OF HEADACHE PAIN

Abstract: The invention is a method for reducing headache pain and symptoms associted with the onset or occurrence of headache in mammals. The method is performed by delivering an invertebrate presynaptic neurotoxin to a mammal extramuscularly (preferably at a localized, site of pain), or at a site in one or more muscles (preferably muscles of the face, cranium and neck). The presynaptic neurotoxins administered according to the invention are those neurotoxins that are known to produce a reversible, flaccid paralysis of muscle tissue in mammals. The preferred neurotoxin for use in the method of the invention is Botulinum toxin, particularly Botulinum toxin A.

Description: METHOD FOR REDUCTION OF HEADACHE PAIN RELATED PATENT APPLICATIONS This is a continuation-in-part of U.S. Patent Application Serial No. 08/240,973, filed June 29, 1994. BACKGROUND OF THE INVENTION 1. Field of the Invention The invention relates to the pharmacological treatment of headache pain. More specifically. the invention relates to the reduction of pain associated with headaches through localized administration of a therapeutically effective dosage of pharmaceutically safe invertebrate exotoxin, in particular Botulinum toxin A. 2. History of the Prior Art "Headache" is a term which encompasses a relatively vast spectrum of common symptoms and sometimes obscure causes. Headaches may be associated with emotional states such as depression and tension, as well as physical events such as muscular tension, neuralgia, neuropathy and vascular disturbances. Although a patient may experience more than one kind of headache pain, the various manifestations of headache are generally believed to have different pathological origins (but see. Olosen, et al., Pain, 46:125-132, 1991 [a model, albeit one unaccepted in the art, which proposes that tension headache shares a causal myofascial component with migraine]). For example, it is generally accepted in the art that the headache condition known as migraine is directly related to vascular changes and events attributable to contraction of the smooth muscles of blood vessels (see, e.g., Wolff, et al., "Headache and Other Head Pain", 1963; and Table 1(a), Row 1), while tension headache originates in skeletal (striated) muscular stress (Table 1(a), Row 2) and other headache pain stems principally from neurological disorders (see, e.g., Table 1 (b)). Although therapies intended to alleviate headache symptoms are abundant, the efficacy of such treatments varies widely. The most common types of headache, together with the perceived pathological origin of the pain and conventional methods for treatment, are summarized in Tables 1 (a)-(b) below: TABLE 1(a) HEADACHES NOT PRIMARILY ASSOCIATED WITH DISORDERS OF THE FACIAL AND CRANIAL NERVES Type Presumed Site Common Mechanism Treatment Migraine Vascular dilation resulting Fronto temp¬ Ergot preparations, (vascular in changes to cerebral oral (uni- or analgesic, anti- headache) blood flow; possible hor¬ bilateral) inflammatory medi-cat- monal origin ions, and serotonin modu¬ lators Tension Vascular disturbance and Generalized Analgesic, anti-infla¬ headache muscle spasm or fatigue mmatory, anti- (the latter is not believed to anxiety and antidepres- be the sant primary origin of pain) medication Meningeal Meningitis Generalized Treat the irritation underlying disease Brain Cancer Varies Treat the tumor underlying disease Temporal Arterial Unilateral, Corϋco- arteritis disorders temporal, steroids occipital Traumatic Head injuries resulting in Varies Varies depending on ori¬ headache subdural hematoma, dysa- depending on gin utonomic cephalalgia or origin other disorders -3- TABLE Kb) HEADACHES PRIMARILY ASSOCIATED WITH DISORDERS OF THE FACIAL AND CRANIAL NERVES Trigeminal neuralgia Trigeminal nerve, Idiopathic, vascular Carbamazepine unilateral disturbances, multiple sclerosis, tumor Atypical facial Unilateral or bilateral Depressive, anxiety Anti-depressant and neuralgia states, idiopathic anti-anxiety medication Orbitally related Unilateral in eye, Idiopathic, parasinus Decongestant nasal neuralgias cheek, ear, neck disorders medication Tolosa-Hunt Unilateral, mainly Arteritis and granu- Corticosteroid Syndrome orbital lomatous lesions therapy Reader's paratri- Unilateral, fronto- Tumors, granulom- Varies depending on geminal syndrome temporal and maxilla atous origin lesions Postzoster syndrome Unilateral, trigeminal Herpes zoster Carbamazepine and divisions anti- depressants Costen's syndrome Unilateral, near Loss of teeth, B ' rte correction, arthritis temporomandi-bular rheumatoid related therapies joints arthritis (Tables 1(a) and 1(b) are adapted from Harrison's Principles of Internal Medicine, 11th Ed., Chapter 6, Tables 6-1 and 6-2 (McGraw-Hill, 1987)). One therapeutic modality for certain neuromuscular disorders which has begun to gain acceptance in recent years is the administration of invertebrate exotoxins in a pharmaceutically safe form. For example, serotype A of the Botulinum toxin has been recommended in the art for use for the treatment of certain diseases such as disorders of the extraocular muscles (e.g., comitant strabismus and nystagmus) as well as dystonias (involuntary contractions of facial muscle) (see, e.g. , The New England Journal of Medicine, 324: 1186-1194, 1991 ). The advantage of using Botulinum toxin A in this context is that it produces a reversible, flaccid paralysis of mammalian skeletal muscle, presumably by blocking the exocytosis of acetylcholine at peripheral, presynaptic cholinergic receptors, with limited activity at receptors in the central nervous system (Rabasseda, et al., Toxicon, 26:329-326, 1988). Additionally, Botulinum toxin A is not believed to result in degeneration of nervous or muscular tissue and has been approved for use in certain therapies by the U.S. Food and Drug Administration. Botulinum toxin A is also presently being tested for its ability to cause the removal of hyperfunctional lines of the face. These tests have demonstrated that Botulinum toxin A may be administered into the musculature of the face without toxic effect to produce localized relaxation of skeletal muscle that lasts as long as six . months (Blitzer, et al., Otolaryngol Head and Neck Surg., 119:1018-1023, 1993). Other serotypes of the Botulinum toxin have been identified that have immunologically distinct phenotypes; i.e., serotypes B, C1 , C2, D, F and G (Simpson, et al., Pharmacol. Rev., 33:155-188, 1981). All of the serotypes are believed to be proteins of about 150 kDa molecular weight that are comprised of two polypeptide chains linked by disulfide bridges. The shorter of the two chains is believed to be responsible for the toxicity of the toxin, while the longer of the two chains is believed to be responsible for the penetration of the toxin into nervous tissue. Although antigenically different to some extent, the Botulinum serotypes are believed to be similar in their pharmacological actions (Brin, et al., "Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology", Neurology, 40:1332-1336, 1990). In addition, like serotype A, serotypes B and E of the Botulinum toxin have been linked to cases of botulism in humans. Thus, having the same pathological activity as serotype A, serotypes B and E can be reasonably expected to have the same therapeutic activity as serotype A in the method of the invention. Other invertebrate toxins are known, or can reasonably be expected, to share the mode of action of Botulinum toxin and/or the toxin's ability to produce reversible, flaccid paralysis of muscles where the toxin is introduced. For example, serotypes A and E of the Botulinum toxin share a substantial degree of sequence homology with the Tetanus neurotoxin produced by Clostridium tetani (DasGupta, et al., Biochemie, 71:1193-1200, 1989). Further, although the tetanus neurotoxin typically acts on the central nervous system to produce rigid rather than flaccid muscle paralysis, at least one peptide digestion fragment of the tetanus toxin (fragment Ibc, which is produced as a papain cleavage product) have been shown to act peripherally to produce flaccid paralysis (Fedinic, et al., Boll. Ist.Sieroter Milan, 64: 35-41 , 1985; and, Gawade, et al., Brain Res., 334:139-46, 1985). Another promising exotoxin-based therapy is the use of Staphylococcal alpha-toxin to stimulate the production of a naturally occurring brain component known as muscle-relaxing factor (MRF). Recently, researchers injected 1 microgram of Staphylococcal alpha-toxin into mice and detected elevated levels of MRF in serum and brain tissue. Reversible, flaccid paralysis of skeletal muscle in the injected mice was also observed (Harshman, et al., Infect.lmmun., 62:421-425, 1994), indicating that S. alpha-toxin also shares the mode of action of Botulinum toxin. Reversible, flaccid paralysis has also been observed following intrathecal injection of acylpolyamine toxins, anticholinergic, presynaptic neurotoxins that are produced in the venom of many invertebrates (Herald, et al., Anesthesiology, 77:507-512, 1992). In particular, two toxins (AR636 and AG489) from spiders Argiope aurantia and Agelenopsis aperta have been shown to produce motor inhibition at a dosage of 2 micrograms while 7 micrograms was an effective dosage to produce sensory inhibition. Despite the apparent effects of such exotoxins on motor and sensory activity in mammals, the use of such toxins in humans to date has been limited. Further, proposals for additional applications for exotoxins use have not included extramuscular applications generally or use in reduction of headache pain specifically. SUMMARY OF THE INVENTION The invention provides a method for reducing headache pain and symptoms in mammals, particularly humans. Specifically, the invention comprises adminis¬ tering a therapeutically effective amount of a pharmaceutically safe invertebrate presynaptic neurotoxin to a mammal. The preferred routes of administration are by extramuscular injection, such as into the perimuscular areas of the face, cranium and neck, as well as into localized sites of pain in these areas. Additional therapeutic benefits can be expected from administering the presynaptic neurotoxins of the invention into one or more striated muscles of the face, cranium and/or neck (including muscles of the shoulder region) muscles in the back. The presynaptic neurotoxins of the invention will be those neurotoxins that can be administered to a mammal to produce localized paralysis of musculature that is reversible (although such paralysis need not necessarily be induced in the practice of the invention) and does not result in degeneration of muscle or nervous tissue. The preferred presynaptic neurotoxin of the invention is Botulinum toxin A. Surprisingly, the method of the invention may not only be applied to reduce headache pain associated with muscle spasm or contraction, but may also be utilized to reduce headache pain associated with vascular disturbances, neuralgia and neuropathy. Even more surprisingly, it has been discovered that reduction of headache pain (particularly vascular headache pain) can be achieved through extramuscular administration of the presynaptic neurotoxins of the invention; i.e., without producing flaccid paralysis of muscle. The method may also be used to reduce symptoms associated with certain kinds of headache pain, such as the premonitory aura experienced by many migraine sufferers. BRIEF DESCRIPTION OF THE DRAWINGS FIGURE 1 is a anatomical drawing depicting the musculature of the human face, cranium and neck. Common target sites (i.e., areas of localized headache pain) are circled; (1) is the frontal and glabella region, (2) is the temporal (right) region, and (3) is the suboccipital region. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS A. PRESYNAPTIC NEUROTOXIN COMPOSITIONS FOR USE IN THE METHOD OF THE INVENTION "Presynaptic neurotoxin" as used in this disclosure refers to both invertebrate toxins and biologically active peptide fragments of proteinaceous invertebrate toxins. The presynaptic neurotoxins of the invention will be those neurotoxins that are known to produce localized, flaccid paralysis of musculature in mammals that is reversible and does not result in degeneration of muscle or nervous tissue. It will be appreciated, however, that the reduction of headache pain which may be achieved according to the method of the invention is apparently independent of the induction of flaccid muscular paralysis which the presynaptic neurotoxins of the invention will produce. Specifically, as described further below, reduction of headache pain may be achieved at dosages of presynaptic neurotoxin which are lower or higher than dosages required to produce flaccid paralysis of skeletal muscle and without introduction of the neurotoxin into muscle tissue. The preferred presynaptic neurotoxin of the invention is Botulinum toxin. Serotype A of this toxin is commercially available and is presently supplied by Allergan, Inc. of Irvine, California under the tradename "BOTOX and by Porton Products Ltd, of the United Kingdom under the tradename "DYSPORT". A pentavalent toxoid of all eight known Botulinum serotypes is also available as an investigational drug from the U.S. Center for Disease Control in Atlanta, Georgia. Of these, the Botulinum A toxin preparations are most preferred for their known safety and efficacy. Tetanus toxins for use as vaccines are also commercially available (from, for example, Lederle Laboratories of Wayne, New Jersey under the tradename 'TETANUS TOXOID PUROGENATED"). As discussed above, the Ibc fragment of the Tetanus toxin is believed to act peripherally and is therefore likely to be similar in its activity to Botulinum toxin. Therefore, the method of the invention will preferably encompass the use of pharmaceutically safe forms of the Ibc fragment of the Tetanus toxin rather than the use of intact Tetanus toxin. Those of ordinary skill in the art will know, or can readily ascertain, how to obtain the presynaptic neurotoxins of the invention, including the Botulinum and Tetanus toxoids, in a pharmaceutically safe form; preferably, a form that is nontetragenic and does not induce a detectable immune response to the toxin antigen. For most of the presynaptic neurotoxins of the invention, pharmaceutical safety will be dose-dependent such that relatively low dosages of toxin will be "safe" as compared to dosages which are known to be sufficient to produce disease. Preferably, the presynaptic neurotoxins of the invention will be administered as a composition in a pharmaceutically acceptable carrier. To that end, presynaptic neurotoxin compositions are prepared for administration by mixing a toxin the desired degree of purity with physiologically acceptable sterile carriers. Such carriers will be nontoxic to recipients at the dosages and concentrations employed. Ordinarily, the preparation of such compositions entails combining the presynaptic neurotoxin with buffers, antioxidants such as ascorbic acid, low molecular weight (less than about 10 residues) polypeptides, proteins, amino acids, carbohydrates including glucose or dextrins, chelating agents such as EDTA, glutathione and other stabilizers and excipients. Such compositions may also be lyophilized and will be pharmaceutically acceptable; i.e., suitably prepared and approved for use in the desired application. Most preferably, the presynaptic neurotoxin will be formulated in unit dosage form for ease of administration. For example, the presynaptic neurotoxin may be supplied as a sterile solution or lyophilized powder in a vial. B. METHODS FOR ADMINISTRATION OF THE PRESYNAPTIC NEUROTOX¬ INS OF THE INVENTION Generally, the dose of presynaptic neurotoxin to be administered will vary with the age, presenting condition and weight of the mammal to be treated. The potency of the presynaptic neurotoxin will also be considered. Toxin potency is . expressed as a mult ; .ole of the LD^ value for a reference mammal, usually a mouse. Where a mouse is the reference mammal, one "unit" of toxin is the amount of toxin that kills 50% of a group of mice that were disease-free prior to inoculation with the toxin. For example, commercially available Botulinum toxin A typically has a potency such that one nanogram contains about 40 mouse units. The potency in humans of the Botulinum toxin A product supplied by Allergan, Inc. under the registered trademark "BOTOX" is believed to be about LD 50 =2,730 units. Assuming a potency which is substantially equivalent to LD 50 =2,730 units, the presynaptic neurotoxin can be administered in a dose of up to about 1 ,000 units, although individual dosages of about 15-30 units are preferred and dosages of as low as about 2.5 to 5 units will have therapeutic efficacy. Generally, the presynaptic neurotoxin will be administered as a composition at a dosage that is proportionally equivalent to about 2.5 cc/100 units. Those of ordinary skill in the art will know, or can readily ascertain, how to adjust these dosages for presynaptic neurotoxin of greater or lesser potency. Preferably, the lowest therapeutically effective dosage (i.e., the dosage which results in detection by the patient of a reduction in the occurrence and/or magnitude of headache pain experienced by the patient, even though other symptoms associated with the pain, such as the premonitory aura associated with vascular headache, may persist) will be injected. In the initial treatment, a low dosage may be administered at one site to determine the patient's sensitivity to, and tolerance of, the neurotoxin. Additional injections of the same or different dosages will be administered as necessary. For example, if headache pain predominates in the frontal cranial region (see, FIGURE 1 ), the patient may receive up to 40 units in the glabella region, and may also receive up to 40 units of the neurotoxin in the mid- forehead region. For headache pain which predominates temporally, laterally and/or suboccipitally, the initial dosage (to be administered extramuscularly) will usually be somewhat lower; e.g., about 10 units per site, followed by up to 40 units per side. For many indications (particularly vascular headaches), extramuscular injection will be the most efficacious route of administration as well as a route which avoids the risk of trauma to muscle tissue. Such injection may, for example, be made subcutaneously or, preferably, perivascularly (to produce infiltration of the neurotoxin into tissue at the target site). If possible, such injections will be made at a localized site of pain associated with the patient's presenting condition ("target site"); e.g., temporal, frontal and/or suboccipital sites in vascular headaches. Those of ordinary skill in the art will be familiar with such target sites and their pathological relationship to headache pain. For example, localized sites of pain known to be associated with the onset of migraine are the oculo-frontal- temporal area of the face and the forehead, with the former predominating in the early stages of migraine onset (see, e.g., Sjaastad, et al., Func.Neurol., 8:27-32, 1993 [fronto-temporal pain is a typical trait of classical migraine]; this reference is incorporated herein by this reference to illustrate knowledge in the art regarding localized sites of headache pain). Common target sites are identified in FIGURE 1. The preferred target site for injection of the presynaptic neurotoxin will be in or near the or extramuscular regions, in particular, target sites of the face, cranium and neck (see, FIGURE 1 ). Although the precise mechanism by which the method of the invention reduces headache pain is not known, it is believed that the efficacy of the method is not necessarily dependent on whether muscle spasm or strain is present in the patient or causally related to the headache pain experienced by the patient. For example, as shown in the data presented in the Examples, the method of the invention was effective in reducing headache pain even in persons who only received an extramuscular injection of presynaptic neurotoxin. Moreover, reduction of headache pain was unexpectedly observed even in patients whose pain was causally related to vascular or neurological components; e.g., classical migraine, trigeminal neuralgia and trauma headache. However, those of ordinary skill in the. art will recognize that additional therapeutic benefits may be achieved through introduction of the presynaptic neurotoxins of the invention into musculature (particularly in the back) where muscle spasm or strain is present. The most preferred target sites are the bilateral temporal, frontal, glabella, and suboccipital areas of the face (see, FIGURE 1 ). The corrugator, procerus, temporal and frontalis muscles are also suitable sites for introduction of the presynaptic neurotoxins of the invention. Localized paralysis in any injected muscle can be monitored visually, by the patient's description of post-injection mobility at the target site musculature, as well as by electromyographical signals obtained at the time of administration of the neurotoxin. For introduction into extramuscluar target sites, the presynaptic neurotoxins of the invention will conveniently be administered by injection. For intramuscular injections, to ensure that the presynaptic neurotoxin is delivered to the target site without substantial systemic distribution, the use of electromyographical ("EMG") injection is recommended. A preferred technique for EMG injection is to introduce the presynaptic neurotoxin through a monopolar hollow bore needle (commonly, one which is coated with a non-stick surface such as 'TEFLON", a trademarked product of DuPont Nemours, of Massachusetts). The needle is placed through the skin and into the target site of a muscle, preferably at a neuromuscular junction. Once the needle has been inserted, the most active site of the muscle can be determined by observation of the EMG signal. Those of ordinary skill in the art will know of, or can readily ascertain, other suitable techniques for administering EMG injections. The injections will be repeated as necessary. As a general guideline, Botulinum toxin A administered into or near muscle tissue according to the method of the invention has been observed to produce flaccid paralysis at target site muscles for up to about 3 to 6 months. Reduction of headache pain in patients who received the presynaptic neurotoxins of the invention extramuscularly has also persisted for extended periods of time. However, Botulinum A toxin in particular is expected to be most effective when administered according to the method of the invention at about 3 month intervals. The invention having been fully described, examples illustrating its practice are set forth below. These examples should not, however, be considered to limit the scope of the invention, which is defined by the appended claims. In the examples, the abbreviation "min" refers to minutes, "hrs" and "h" refer to hours, "mo" and "mos" refers to months, "yr" and "yrs" refer to years, and measurement units (such as "ml") are referred to by standard abbreviations. Also, "F" refers to female and "M" refers to male. Further, in Examples I and II, the following symbols indicate trademarks of the companies listed below: ■ Trademarked product of Sandoz Pharmaceuticals. ■■ Trademarked product of Bristol-Myers Laboratories ■■■ Trademarked product of Stuart Pharmaceuticalus ■■■■ Trademarked product of Syntex Pharmaceuticals ■■■■■ Trademarked product of Merck, Sharp & Dohme Pharmaceuticals ■■■■■■ Trademarked product of Schering Drug • Trademarked product of Winthrop-Breon o Trademarked product of Eli Lilly Pharmaceuticals * Trademarked product of Roche Products t Trademarked product of DuPont ■ Trademarked product of Ayerst Pharmaceuticals j Trademarked product of Cerenex Pharmaceuticals EXAMPLE I ADMINISTRATION OF BOTULINUM TOXIN A TO REDUCE HEADACHE PAIN IN HUMANS Over a period of 6 months, 162 patients received 1 to 2 injections of Botulinum toxin A ("BOTOX"), reconstituted with saline to a concentration of 2.5 cc 100 units. The toxin was administered intramuscularly by EMG injection into the frontalis, corrugator, procerus and/or platysma muscles of the face. The patients were participants in a clinical trial of the use of Botulinum toxin A to temporarily remove facial wrinkles. Of the patients who received the injections, 11 spontaneously reported a prior case history of headache pain ("headache group" patients). Of the headache group patients, 5 had a prior history of migraine, 1 had previously been diagnosed as having trigeminal neuralgia, and the remainder suffered from frequent "tension" headaches (i.e., at an occurrence of at least 3 times a week). Of the patients reporting a prior history of migraine, two reported that they were suffering from an attack at the time that the injection was administered. One of these patients was experiencing headache pain, while the other was experiencing premonitory symptoms of migraine; i.e., a visual aura. The patient with trigeminal neuralgia had previously been treated pharmacologically without substantial reduction of her symptoms. All of the 11 patients in the headache group reported that they were either free of headaches or suffered substantially reduced headache pain (as evaluated subjectively by the patient) for periods of up to 6 months following treatment. The two patients who had reported that they were experiencing migraine symptoms at the time of treatment reported that the symptoms completely dissipated after 1 to 1 1/2 hrs. Additional details of the case history, treatment, and post-treatment history of patients within the headache group who agreed to the provide such information are TABLE 2 Dosage and Age/ Presenting Site of Frequency Post Injection Sex Condition Prior Treatment Delivery of Injection Condition 42/F Periodic CAFERGOT- Corrugator 12 units, 1 time; No migraine pain migraines (ergotamine and procerus 15 units, 1 time. for 7 mos over 7-8 years tart rate) Administered over a 7 mos interval. 42/F Severe STADOL" (butor- Corrugator 16 units, 3 times; 22 No migraine pain migraine, phanoltartrate) and procerus units, for 3 mos.; one at¬ at about 2 analgesic and 2 times. tack ended 1h, 15 week ELAVIL— Administered min after dosing; m x intervals since 4 times/day (anti- over a 3 on 2nd occasion age 8 years depressant) and mos interval. pain at < NAPROSYN ■■■■ end of migraine r at 500 mg/day (anti- cycle ended 30 min inflammatory) after dosing 38/F Migraine No detail available Corrugator 16 units, 1 time; No migraine pain sufferer, and procerus 20 units, 1 time. for more than six no detail Administered over months available about a one mos re history interval. SUBSTITUTE SHEET (RULE 261 D d ae aos g n -16- / A P P Sifiti P Iji Ftttg e r sn r o r een g o r e q uence osnecon y T C dii C jlitif Ii D ttditt ex r enoamenono oneceve ry nonon unsmeaeaace p an , , co rg a r r ce a pr oxmae y o an ms pr oceus un r onaos , . ove r mon p aeo. EXAMPLE II Additional patients ("pt.") were treated using the method described in Example I, with particular emphasis on extramuscular injections of the Botulinum A toxin in the frontal, suboccipital and temporal regions of the face. The only adverse effect of the injection reported by any patient was soreness at the injection site, particularly at intramuscular injection sites. The results of the treatment received by each patient are reported in Table 3, below. A / P i P Ijittt n g eseosnco r en g en S C di C diiitt exnononono 1 H hd2i G lll 53 A 1193d hdhtb 7 /9 f/ht tt / u snsaes o : e p wa q uasaeve r eeaacesa ; soe , . i G b/ i " S iblfiiii) 5lll 10/293 i Iidh (t9 t u a snneoss y o man onsaeasa yg: ce r ecvee pgr e rg n , BT fh l8 OOX l 6 7ih th ttt tt s r u am mo r ea y eas woosons a g o- ,, [ i iihdh] h tt o m y m pr emn y s yp gr anesecaveo r momsaaes. h b Br ih li ld llliiid " tt tt n gg oeen com p ee y suoses emnae , . , d di i ifi t t ryr na p oucsnes y p an. « •* > M hf'tt tt os o p s cu g a r eo rr o. UJ -J ld 3 ftit musceuoeu r ncn r ne CO < hhtf ijtit t mos r n aeenecon , I- lhhd ht h hdtt ao g a nu p asoa. hdhi fth 3 aeaneac p onoe rr a lf ftidtt ue ae r msceunconu r r ne.. 1 " o o Φ .t_ O ♦- 1 c Φ ε CD 2 o 1- _? __ .o a CO '__ Q. o ■ Age/ Prior Treatment Site of Delivery Presenting Post Injection Sex Condition Condition 42/F Stadol" now. In past 16 units, Glabella 1023/92; Onset - 8 years of age; Pt. had a migraine when treated - Cafergot" 16 units , Glabella 6/11/93; Cheese/Chocolate/Stress - on 4/13/94. Within 30 min. 10 units, Forehead 6/30/93; set off headaches (possibly nausea ended; within 1.5 hours, 6 units (booster), Glabella of migraine origin); the migraine pain ended. No 6/30/93; Symptoms: Pain "severe", migraine headache pain for 3 22 units, suboccipital (left side) nausea; months after each treatment. 1/13/94; Frequency: Every 2 weeks NOTE: 22 units, suboccipital (right side) until head injury, 7/94. Flaccid paralysis of the 4/13/94; Frequency increased, corrugator and procerus SO 20 units each, Glabella and with additional parietal and muscles was achieved on June I Bilateral Temporal 6/10/94; suboccipital pain not 11 , 1993. However, elimination 10 units each, Left parietal, experienced in past migraine of pain was not achieved until left and right suboccipital history. injections given on 6/30/93. 9/14/94; Elimination of headache pain in 10 units left suboccipital and 20 the left suboccipital region units bilateral temporal 9/30/94 achieved on 1/13/94; elimination (Forehead, bilateral temporal of pain in the right suboccipital and suboccipital injections not region achieved 4/13/94. Pain into muscle). associated with head injury relieved within several hours of injection. However, pt. reports occasional occurrence of A / P i Ij P itttg ee r enn g osncseon S C C diidiitt exoonoonnn 45 ibd 16i G lbll 3f P t bii/25/94 A f ij ti fi ti t t r n ann unsaa ; u p oec g a ex pr encn g es o r ee g n p ee i vn r sneco-. , , *ht d h f 20i G lbll 4154 hdt//9 hd hdh tht i o r e r us q unsaea g p r euen seve r eeaacas noa y eaaeae ancn , i 16i G lbll 6/4 (iblfiit29/9 fb 6 h H t t u p nsnsaea r ua p os y o m gr ao aoswve r ne ■ monoe , . , r ii d i)hih iji ttt t t o g seconn wou pr emonencon waso ry e id b 9 t id flid tt s y mmu y r q u r o p os aoea rg oeeuceaccs an. lifl s p a r a y s o muces. A hi 500 15i G lbll 2t P Sf hdt/18/94 hdd i r i fh t hhhh tt ceoe p nu unsaemna o r eaaca ; ane r s seveeeseeaacene g ,, . 1h (6i Fd 2/14 l iblfii ii t8/9 t i M h 194)9 m gp o y unso r eea ; p ss o m gr ane o r emo r a a g n r eana r c. , , . 23i Fhdb k f 9/9/94 l tt t u r aon r nsoeeau oce a weeoas , Fhd iji 10 I ( i hih ttt O b 7 t tt ftt n y o r eeaneco noosea r snens iy r an g ne r weuseso r ao mon. , l f) l d flit tt th fiftt u r om msce g moe r aeo ex r eoownmee r s se o.. M h dh iji t t did r i ttt osaeaces a pp eanecons r o p no ex p eence , . b d ih lft hdt thi h ee cen r enee an y eaace p an ove r e r . tl N fhdd flt me prr eo r eea aoa aao u p e rr onn p a. iitl H tit pr emono ry s y m p oms c r ana r e g w r onoeve p .. , . P tld r id htitiit r asoe p o r e ex p en r e p o ry enc g evn g pr emono r a. i ih t tldhtft somae p nneem p o nausea ans r a oe r s y m p om o dibl jiiit mauna r n a r ea m gr eoan.. . "5 D M T Jitillid on p oan aso r eeven «•- o lfidft f e se oace. Φ ,t_ OT c φ 4 E-* co 2 1- _. o * C o. y ∞_ y_ ** P A /i P Ijitttrg esen g oeennnsco i C di S t C diit xeonoononn R E 254flil R f f dibdt i di bi mu r av"" gr ses r omonesce cnon ase g -... i dd t " i " t i h t tf mes a y; m r avaoeeo see r ao r v r emnm pr oemen oe N 500 hdh dil P hdh i t ea pr osnaca yy """eaesacae p an -.. dil didiht m w g a y; asa g wnose. hiid t hh c r oncsoneneaaces 4 blit y e r s a y a g o a neu r o g so. R bd h il aennae seve r ca r . idt bf acencseo r e r iih di d t x e p eencn g eagneos iid P dtt t connoooes n.. i it exen p e r ce p remno r o y t s y mm p os. 9. m C. CO JO " 55 Φ .> _Q CD " Φ ϋ Q O ή c Φ 3 .*__ O (0 *_ c φ * E-» £ _- '_z Q. O CO Age/ Prior Treatment Site of Delivery Presenting Post Injection Sex Condition Condition 44/F Aspirin 16 units, Glabella 4/15/94; Onset: early 30's. During the period between 12 units, Glabella 5/27/94 Tension, headaches receiving the first and second nearly every morning. injections, pt. reports that she On a scale of 1 - 10, did not have any headache patient rated her pain. Pt. did have a headache headaches 3 - 4. on the morning of 5/27/94 (date of 2nd injection) which was relieved by aspirin. I I Age/ Prior Treatment Site of Delivery Presenting Post Injection Sex Condition Condition 40/F Aspirin 10 units, Crow's feet area Frequent headaches Since injections given over the 10/6/93; (probably tension course of last 6 months, pt. 15 units, Glabella 10//93; headaches). reports that she has not had any 20 units, Forehead 10/6/93; headache pain for approximately 20 units, Crow's feet 4/25/94; 1 year. 8 units, Chin 4/25/94; 20 units, Crow's feet 5/27/94; 15 units, Crow's feet 7/15/94 (Forehead and Crow's feet area injections not into muscle) I Age/ Prior Treatment Site of Delivery Presenting Post Injection Sex Condition Condition 57/F 2 Tablets Fiorinal 10 units, Crow's feet 12/4/92; Pt. described headache On 3/25/94, pt. reported having (butalbinal) 20 units, Crow's feet 3/25/94; pain as "a crushing" pain no headache pain for first 7 w/Codeine" 15 units, Glabella 3/25/94 in the forehead and weeks after receiving the first (Crow's feet injection not into temporal areas that injection. She reported having 1 muscle) occurs about 1 time/week headache in the 8th week which and is associated with eye was "weaker" in severity than strain. headache pain she recalled having prior to receiving the injections. - - Iji P tt Pi A /t nconenos r esen gg e dii C di C ti S t ononononex h k R t f fi 6 di G tt t t D il hhlbll 3/14 12t8/9r es saesao r s wee p ana y eaac u i saea ; n , . B ij tih 4 4t M b bi bhd (f t ht 24i G lbllttt + r ooxnecon r c ae ona r ou g s r esssa on y uo sesaen , . ,, h d i d 193 ti bid9i th G lblltt se no ece an y x p e r enoo s unsesaea ,, h i " d R hd " f / h 3/494) e p acanaeweaa ; a r ea.. hk dft fi 6 F h t ihd 36t 6 7 /94 cees / as ae rr s we ; easo r ee una , , r idh dbh " b t Ll G 9/94 t 8itlbll 6/2t uesceem asmcausa ; une r aea , k " i H i i C 4 t 2' f 8/2490tt/ n s r v r we r eve y owee ; eas r owsee un , . , lbililbll) ( i G lbll t 169/30/94t e musce mea onco yg aa unsea ;, hdh f M tf t idil Fhd t 12t r nee r e q un y e r euec o usea r noeea , , hddi'h it 94 t 9/30/ enseaacesc r ase p ane. ' fd fhd ( C t ewse an r oo r eea ijti il)tt ons noo munecnsce G h f 6hf t O 0 lbll 22 A ihld R t tt A 2 10t/2/93t tt sene r e p o r ao r s a r s :g i saa ; ceom p en co r monnee une. ,, . G iihh Fl ilbll t fi ijti R 12t 5 7 /93 t t / sn gr ss com p eso r cevesneconse r e q uenc y: e g ua r unaea ;r ese , G li h h 5ilbll 11 fhd d i didt hdhdhi 1t/5 / 933 t ; aso r eeaeownn nove an y eaeseaacemes unaea ; acs. , G ilb dk ki 16ll 5 /27/94 M i t m r p e r we r ane unsaeaa r ooe g . , _r hdhi 1 t eaamece - 1 φ hihtt p e r mon w Q 4- it pr emnou r o ry aas. o φ . _ tn ♦4 C Φ 4 E_* CO £ 1- c _. • c o • c ' 5. CO Q. < CO o •* in Age/ Prior Treatment Site of Delivery Presenting Post Injection Sex Condition Condition 41 /F Fiorinal and Fiorinal 18 units, Glabella 6/29/94 For the last 7 - 8 years 3 months after receiving the with Codeine"; pt. had migraine injection, pt. reports that she has Demerol(meperi-dine headaches several not had a migraine. However, pt. HCL) « at hospital with times per month with has had 3 headaches which she severe attack premonitory aura. describes as "mild". 41/F Aspirin 18 units, Glabella 3/9/94; Headaches 1 time 6 months after receiving the first 20 units, Glabella 7/15/94 a week of moderate injection, pt. reports that she has severity. Area of not experienced a headache. headache = over I N> VO frontal region and I forehead. Age/ Prior Treatment Site of Delivery Presenting Post Injection Sex Condition Condition 47/F Ibuprofen 17.5 units, Glabella 8/3/94; Frequent headaches Patient complained of headache 20 units, Crow's feet 9/30/94; described as a dull at injection site for first 2 days. 20 units, Bilateral Temporal ache over forehead, As of 9/16/94, still having daily 9/30/94 temporal areas and headaches. However, patient (Crow's feet and temporal back of head. Pt. also states a decrease in severity. injections not into muscle) reports some pain in She still has movement in the the temporal glabella area. mandibular joint. As of 10/7/94: After injection on I 9/30/94 (given to temporal o I region), pt. reports headache in forehead area eliminated.. TMJ pain also described as being "improved". Age/ Prior Treatment Site of Delivery Presenting Post Injection Sex Condition Condition 54/F Imitrex 16 units, Glabella 8/26/94; Age of onset: 4 years. As of 9/16/94: After initial (sumatriptan 10 units, Right Suboccipital Frequency: Daily. injection pt. reported a general succinate)j; Darvon 9/30/94; Diagnosed as migraine. decrease in headache intensity (propoxyphene 20 units, Bilateral Temporal Precipitating events: and no headache pain in HCL)o. Taking Imitrex 9/30/94; heat, using computer, glabella area. After second during treatment 10 units, Left Suboccipital chocolate, stress, injections (R. suboccip.), patient 9/30/94 allergies to pollen. reported decrease in headache (Latter three not into muscle) Signs and Symptoms: pain at injection site (back of Pain in back of neck neck on that side) and a further I and flashing lights. decrease in pain intensity in other I Reports 12+ pain on areas (i.e. back of eyes and scale of 1 -10 when she other side of neck). Patient is no doesn't take Elavil longer using Im ' itrex for pain 25 mg. (Note: patient relief. Has used Darvon or was using Im ' itrex daily Valium to relieve headache pain + 2 Darvons + 10 mg only once since last injection and of Valium daily which reports that she no longer would give minimal experiences the onset of relief to headache). migraine on exposure to a precipitating event. i P i P Ijttt A /r esnn g osnecoen g e i C dii C ditt Snonononoxe R ldi i (id 15i G lbll 9/1/94 Dh A f 9/16/94)dit Ce g u r ana ; es o g rna g ose uneame r o : no maessoene ,, iid Fi i f 15ihd 9/1/94l i j Fiil t t tt m g an sm p oc r nes a r e q u uno r eea ; ncee r aneonensona r ". ,, di hlll H hh h 20 B i T ht ttill iti rt t ttt ensna r mow r p oeaaces unseae p o r ane p eneve r e p osa se s aceom , . , . P iii hi hhh V i 9/30 dh ttt/94 t t r e pg asnsonscan evens : auseeaaceou g r o , r ihiill b il d ib hi (L) b ttttt t t n g w nn muesc r esen g sn g onae r ooosceem asw hd l il " hh ild " i t rte r emaaces suc asnave y cea , . llhht smes weae r can g es ,, G O A 1lbll 84l A /d t6 R l 185i/24/9 D (f f 919/94 R h tl rt tt nse : a ; us o p g ee g u unsaee r aze p am r oeaa r amane , ... (did) i i 20ih G lblld hill h hdhd HC L) ti t t ca g nose m g an uaaea an se saeaa r es anns esensonces. , l f Bill (l i ihk fht ti ltttt ti bd t t t nmess r e q ueaae p o r aae r no w ne p n r ensone r nocanuooeea , hd h H idh l) R lhh tt rteaaces mu p nseaacscea ao r sa seee p o.... h l d i fhd hditd iti ocaeno r eeas nona anna a m gr ae bkf h P idhiiiht t ac o e r sa ex p ceseaace snevn g ee r ence r ec.. liii ij4i A f 1010/9t/ cassc m gr anecsne au r aon o , . , iti l fhdifi O t nausea vom g o r anosseea p n r un g n oe r n ,, . i 1ii 0/20 hdi iiht t P t conscousness amanan r es seve r e p an g . id ltf t idf hdl bld t a r aes ove r e seaem p o r aau oe a r ea nause rr e. ,, __ • Φ ii A bft 2 ht u vson a r o r se.. .> " Φ ijii 10dt/20 nnecons o p an an , Q o ldtt r eae s y m p omsone g . C Φ * ε- re £ 1- .2 * _z 0. u m_ « CO_ ■ f CM Ij P i P ittt A / n r esenn g osecon g e C dii C diitt Sonnononoxe ij P h ff d f r ii S iti h tdt rt tt as su r emncenecon p r epose r o p eoca. , . iih h ri d ih lihttt seas no p e m gr ane w g exence an y hdh i ildt ae p nnoe r ance nausea aneaca , . bldii fl u rr e vsono r seve r a ll y ea r s as w a meso r e , di hdht t moe r aeensoneaace i P ii lliild a p p ann r ma ry ocaze. i fldlt t n r ona anem pr a r eao as. P i hlll4 A f 10/144 t ff d f 20i G b 9/30/9di /9h tt C f C tt tt t n ; s oaeas sue r erom unsaea ; ene ; p r e p o r saae rg oo" , , . lll h " ii " f 20i Bil T B hdii 10 t A idt /6 ttt vascua r m gr aneso r o r unsae r aem p o r a ; a sea a m gr ne onven pr essanseae , 142i L ih 21ih i r i r il 9/30/941/9/90fki i ttt blk ( ttt t t u w y ea r s w p an p ma y ; nse g ou pr emon ry s y m p oce r sanooms ,, hl r i h idf h hd T i) hh dibd t t dt tt tt one g s r em p o r ana ses r ee oeeau r n gr eameec as. ijti i h (Lt " diiid " Htt tt t ae r wonecons nonomnse r p oweve. , . P ii l) i S d hitttt rt mu rr ec p an g evens :r on g scee p oeavn g a seve r e lli b r ih lihii 1012 btt rt /ttdt smes gg s cean m gr ane onu sae ,,, fdhh h r ihh tt tilh lf t t oos suc aae p s ceesee r n g an was on y onee , hiiii t fddf h hd P dtt rt yr amneconann g oos se oe r e rp aeoe- , .. 9. o dihlifft C. hh t h hdlttt r e wne cocoae caenea seas noa an y cuse r,, . TO JO A dff hdhtiiii u r a an su y noeaacsee p an snce r ecevn g . " 53 Φ .> -Q St dii co d ijity m p mos : zzness seconnecon , . "Φ Q i nausea p an , . 4- 13 o c φ 3 O O CM 4- c φ ε re £ H c k. "C_ .2 'CM * ■_ * 0. < LL LL TO CM

Claims: CLAIMS 1. A method for reduction of pain associated with headache in a mammal comprising administering a therapeutically effective amount of an invertebrate presynaptic neurotoxin in a pharmaceutically safe form to the mammal by delivery of the presynaptic neurotoxin into one or more muscles. 2. The method according to Claim 1 wherein the neurotoxin is delivered to one or more muscles of the face, cranium and neck. 3. The method according to Claim 2 wherein the presynaptic neurotoxin is delivered to one or more of the frontalis, corrugator, procerus and bilateral temporal muscles. 4. The method according to Claim 2 wherein the presynaptic neurotoxin is also delivered to one or more muscles of the mammal's back. 5. The method according to Claim 1 wherein the presynaptic neurotoxin is administered by electromyographical injection into the muscle. 6. The method according to Claim 1 wherein the presynaptic neurotoxin is administered by injection into muscle in the area of a neuromuscular junction. 7. The method according to Claim 1 wherein the presynaptic neurotoxin is a Botulinum toxin. 8. The method according to Claim 6 wherein the Botulinum toxin is Botulinum toxin A. 9. . The method according to Claim 1 wherein the presynaptic neurotoxin is a biologically active fragment of a proteinaceous toxin. 10. The method according to Claim 8 wherein the biologically active fragment is the Ibc fragment of the Tetanus toxin. 11. A method for reduction of symptoms associated with the onset or presence of headache in a mammal comprising administering a therapeutically effective amount of an invertebrate presynaptic neurotoxin in a pharmaceutically safe form to the mammal by delivery of the presynaptic neurotoxin into one or more muscles. 12. A method for reduction of pain associated with headache in a mammal comprising administering a therapeutically effective amount of an invertebrate presynaptic neurotoxin in a pharmaceutically safe form to the mammal by delivery of the presynaptic neurotoxin to an extramuscular site of the face, cranium or neck. 13. The method according to Claim 12 wherein the neurotoxin is delivered to one or more target sites of the headache pain experienced by the mammal. 14. The method according to Claim 13 wherein the presynaptic neurotoxin is delivered to one or more of the frontal, temporal and suboccipital areas of the face. 15. The method according to Claim 12 wherein the presynaptic neurotoxin is administered by perivascular injection. 16. The method according to Claim 12 wherein the presynaptic neurotoxin is administered by subcutaneous injection. 17. The method according to Claim 12 wherein the presynaptic neurotoxin is a Botulinum toxin. 18. The method according to Claim 17 wherein the Botulinum toxin is Botulinum toxin A. 19. The method according to Claim 12 wherein the presynaptic neurotoxin is a biologically active fragment of a proteinaceous toxin. 20. The method according to Claim 19 wherein the biologically active fragment is the Ibc fragment of the Tetanus toxin. 21. A method for reduction of symptoms associated with the onset or presence of headache in a mammal comprising administering a therapeutically effective amount of an invertebrate presynaptic neurotoxin in a pharmaceutically safe form to the mammal by delivery of the presynaptic neurotoxin to an extramuscular site in the face, cranium or neck.

Inventors: BINDER WILLIAM J, BINDER, WILLIAM, J.
Applicants: BINDER WILLIAM J, BINDER, WILLIAM, J.
Application year: 1995
Main classification: A61K38
IPC codes: A61K9, A61K38, A61K45, A61P25, A61P29